Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PEN

Penumbra Inc

318.10

Jul 10 • 04:00PM ET +0.15 (0.05%)

Healthcare Medical Devices USA Large NYSE

Peers: BSX EW MASI SYK ZBH MDT ISRG IART TFX BAX

| Held by: IJH VTI VB VBK VXF MDY IJK IWP SPMD XMMO

Scroll to Statements

Index	-
Market Cap	12.51B
Enterprise Value	12.11B
Income	171.05M
Sales	1.45B
Book/sh	37.48
Cash/sh	15.65
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	4700
IPO	Sep 18, 2015

P/E	73.20
Forward P/E	51.61
PEG	2.18
P/S	8.60
P/B	8.49
P/C	20.32
P/FCF	58.81
EV/EBITDA	59.33
EV/Sales	8.33
Quick Ratio	3.95
Current Ratio	6.02
Debt/Eq	0.15
LT Debt/Eq	0.14
Option/Short	Yes / Yes

EPS (ttm)	4.35
EPS next Y	6.16
EPS next Q	1.16
EPS this Y	27.74%
EPS next Y	25.65%
EPS next 5Y	23.72%
EPS past 3/5Y	- -
Sales past 3/5Y	18.33% 20.16%
EPS Y/Y TTM	295.44%
Sales Y/Y TTM	17.27%
EPS Q/Q	-17.72%
Sales Q/Q	15.62%
Earnings	May 06 AMC
EPS/Sales Surpr.	-21.02% 1.16%

Insider Own	2.82%
Insider Trans	-0.23%
Inst Own	85.97%
Inst Trans	-7.62%
ROA	9.80%
ROE	12.73%
ROIC	10.22%
Gross Margin	66.60%
Oper. Margin	12.87%
Profit Margin	11.76%
SMA20	0.23%
SMA50	-0.83%
SMA200	2.35%
Trades

Shs Outstand	39.32M
Shs Float	38.22M
Short Float	5.33%
Short Ratio	4.68
Short Interest	2.04M
52W High	362.41 -12.23%
52W Low	221.26 43.77%
Volatility	0.53% 0.67%
ATR (14)	2.17
RSI (14)	47.62
Beta	0.70
Rel Volume	0.34
Avg Volume	435.75K
Volume	146,602

Perf Week	-0.15%
Perf Month	-0.92%
Perf Quarter	-3.47%
Perf Half Y	0.62%
Perf YTD	2.31%
Perf Year	30.44%
Perf 3Y	-2.80%
Perf 5Y	15.02%
Perf 10Y	425.87%
Recom	2.83
Target Price	364.25
Prev Close	317.95
Price	318.10
Change	0.05%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-25	Upgrade	JP Morgan	Neutral → Overweight	$370
Dec-11-25	Upgrade	Citigroup	Neutral → Buy	$350
Nov-18-25	Initiated	Wells Fargo	Underweight	$15
Oct-08-25	Upgrade	Needham	Hold → Buy	$326
Sep-02-25	Initiated	Evercore ISI	Outperform	$300
Mar-14-25	Initiated	BofA Securities	Buy	$320
Jan-21-25	Initiated	UBS	Buy	$305
Dec-17-24	Initiated	Oppenheimer	Outperform	$275
Dec-11-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$190 → $275
Sep-18-24	Initiated	Stifel	Buy	$238
Sep-03-24	Initiated	Leerink Partners	Outperform	$263
Jul-31-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$289 → $150
Jul-31-24	Downgrade	Citigroup	Buy → Neutral	$165 → $178
Feb-23-24	Downgrade	JP Morgan	Overweight → Neutral	$284 → $250
Sep-06-23	Initiated	Morgan Stanley	Equal-Weight	$265
Jul-19-23	Initiated	Robert W. Baird	Outperform	$375
Mar-29-23	Downgrade	Needham	Buy → Hold
Jan-30-23	Initiated	Piper Sandler	Overweight	$275
Nov-04-22	Upgrade	Citigroup	Neutral → Buy	$217 → $212
Oct-12-22	Initiated	Jefferies	Buy	$230

Show Previous Ratings

Jul-07-26 09:00AM	First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke (PR Newswire)
Jun-18-26 06:00AM	Penumbra wins CE mark for Thunderbolt clot removal tech (MedTech Dive)
Jun-17-26 07:00AM	Medtech M&A maintains momentum following decade-high 2025: PwC (MedTech Dive)
Jun-16-26 12:27PM	Penumbras Thunderbolt approval poised to accelerate neuro thrombectomy innovation (Medical Device Network)
Jun-15-26 09:00AM	Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT (PR Newswire)
11:34AM	Loading…
Jun-12-26 11:34AM	FDA clears Penumbras Thunderbolt thrombectomy platform for stroke (Medical Device Network)
07:22AM	Penumbras FDA nod for clot removal tech a win for Boston Scientific (MedTech Dive)
Jun-11-26 04:05PM	Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke (PR Newswire)
May-06-26 04:22PM	Penumbra: Q1 Earnings Snapshot (Associated Press)
04:05PM	Penumbra, Inc. Reports First Quarter 2026 Financial Results (PR Newswire)
Apr-20-26 11:18AM	EY on the current state of the medtech industry (Medical Device Network)
Apr-13-26 09:00AM	New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients (PR Newswire)
Apr-10-26 01:41PM	Are OMEX, PEN, SNCY, CWAN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Apr-09-26 11:40AM	E2 raises $80M to market thrombectomy platform (MedTech Dive)
Mar-31-26 11:19AM	Are EHAB, SLAB, PEN, SKYT Obtaining Fair Deals for their Shareholders? (PR Newswire)
04:39PM	Loading…
Mar-02-26 04:39PM	Are PEN, STKL, BCO, LNKB Obtaining Fair Deals for their Shareholders? (PR Newswire)
07:41AM	PEN Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise (Zacks)
Feb-25-26 10:56PM	Analyst Report: Penumbra, Inc. (Morningstar Research)
04:30PM	Compared to Estimates, Penumbra (PEN) Q4 Earnings: A Look at Key Metrics (Zacks)
04:15PM	Penumbra (PEN) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:06PM	Penumbra (NYSE:PEN) Reports Bullish Q4 CY2025 (StockStory)
01:29PM	Penumbra: Q4 Earnings Snapshot (Associated Press Finance)
01:00PM	Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
Feb-24-26 11:40AM	CLPBY or PEN: Which Is the Better Value Stock Right Now? (Zacks)
Feb-22-26 07:47AM	Nvidia earnings, SCOTUS tariff fallout, geopolitical tensions rise: What to watch this week (Yahoo Finance)
Feb-06-26 08:19AM	Penumbra (PEN) Reported Revenue Growth of 16.9% in Q4 (Insider Monkey)
Feb-05-26 05:44AM	J.P. Morgan Healthcare Conference 2026 Report (Pharmaceutical Technology)
12:07AM	Boston Scientific Q4 Earnings Call Highlights (MarketBeat)
Feb-04-26 08:02AM	Boston Scientific shares slide on cautious 2026 revenue forecast (Reuters)
06:30AM	Boston Scientific announces results for fourth quarter and full year 2025 (PR Newswire)
09:32PM	Loading…
Feb-03-26 09:32PM	Penumbra, Inc. (PEN): A Bull Case Theory (Insider Monkey)
11:40AM	GMED vs. PEN: Which Stock Is the Better Value Option? (Zacks)
Feb-01-26 11:13PM	Deal fever returns: 2026 looks hot for M&A (TheStreet)
Jan-28-26 06:41PM	Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Jan-24-26 01:18AM	Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. (Barrons.com)
Jan-21-26 12:30PM	Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface (Benzinga)
12:41AM	Halper Sadeh LLC Encourages PEN, FONR, GDOT Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Jan-20-26 11:03PM	3 Reasons to Sell PEN and 1 Stock to Buy Instead (StockStory)
05:52AM	3 takeaways from Boston Scientifics $14.5B Penumbra deal (MedTech Dive)
Jan-19-26 10:10AM	Podcast: JPM26s dealmaking falls short of expectations (Pharmaceutical Technology)
Jan-18-26 11:33PM	3 High-Flying Stocks That Fall Short (StockStory)
Jan-17-26 04:30AM	Investing.coms stocks of the week (Investing.com)
Jan-16-26 11:33AM	Penumbra (PEN) Climbs to All-Time High on $14.5-Billion Merger (Insider Monkey)
05:46AM	Penumbra (PEN) Moves 11.8% Higher: Will This Strength Last? (Zacks)
Jan-15-26 06:35PM	Analyst Report: Penumbra, Inc. (Morningstar Research) +11.82%
05:34PM	Podcast: Chips, Banks Boost Markets (The Wall Street Journal)
04:33PM	Stocks Boosted by Chip Demand Optimism (Barchart)
04:25PM	Stocks to Watch Thursday: Penumbra, BlackRock, Goldman Sachs (The Wall Street Journal)
04:16PM	Lightning Flashes As Boston Scientific Takes Over Penumbra For $14.5 Billion (Investor's Business Daily)
01:23PM	JPM26: Boston Scientific acquires Penumbra in $14.5bn deal (Medical Device Network)
01:11PM	Wall Street Soars Near Records, AMD And ASML Jump 6%: What's Moving Markets Thursday? (Benzinga)
12:51PM	Why Penumbra (PEN) Stock Is Trading Up Today (StockStory)
10:17AM	Boston Scientific Agrees to Buy Penumbra in $14.6 Billion Cardiovascular Deal (GuruFocus.com)
09:37AM	Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock (The Wall Street Journal)
09:23AM	BlackRock earnings, Spotify to raise premium price in the US (Yahoo Finance Video)
09:03AM	Boston Scientific Will Buy Penumbra In $14.5 Billion Medtech Deal (Investor's Business Daily)
08:45AM	Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. (Barrons.com)
08:42AM	Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy (Benzinga)
08:38AM	Penumbra surges on news of $14.5 billion Boston Scientific buyout, BSX down (Investing.com)
08:11AM	Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to 'fast-growing' vascular segments (MarketWatch)
07:25AM	Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock (The Wall Street Journal)
07:13AM	Boston Scientific to buy Penumbra in $14.5 billion deal (Reuters)
07:00AM	Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
07:00AM	Boston Scientific announces agreement to acquire Penumbra, Inc. (PR Newswire)
Jan-13-26 01:04PM	Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? (Benzinga) -5.79%
Jan-12-26 11:40AM	CLPBY vs. PEN: Which Stock Is the Better Value Option? (Zacks)
09:50AM	Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-07-26 12:45PM	Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Dec-31-25 09:45AM	Here's Why Penumbra (PEN) is a Strong Growth Stock (Zacks)
Dec-29-25 04:30PM	Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-26-25 07:17AM	Reasons to Retain Penumbra Stock in Your Portfolio for Now (Zacks)
Dec-22-25 07:30AM	NeuroOne(R) Appoints Jason Mills to the Board of Directors (NewMediaWire)
Dec-19-25 04:05PM	Stocks At New Highs: Industrials Allient, Wabtec And A Health Care Name Trade In Or Near Buy Zones (Investor's Business Daily)
Dec-15-25 09:45AM	Here's Why Penumbra (PEN) is a Strong Growth Stock (Zacks)
Dec-11-25 01:55PM	Stock Market Today: Dow Jumps, Nasdaq Trims Losses; Boot Barn, ATI, Penumbra Shares Break Out (Live Coverage) (Investor's Business Daily)
Dec-10-25 11:33PM	3 Profitable Stocks That Fall Short (StockStory) +5.55%
Dec-05-25 04:29PM	IBD Stock Of The Day Breaks Out, Lays The Groundwork For 2026 Acceleration (Investor's Business Daily)
01:44PM	IBD Stock Of The Day Penumbra Lays The Groundwork For 2026 Acceleration (Investor's Business Daily)
Dec-03-25 11:40AM	GMED or PEN: Which Is the Better Value Stock Right Now? (Zacks)
Nov-27-25 09:45AM	Here's Why Penumbra (PEN) is a Strong Growth Stock (Zacks)
Nov-25-25 10:31PM	Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 In Review: Penumbra (NYSE:PEN) Vs Peers (StockStory)
Nov-24-25 06:36PM	Analyst Report: Penumbra, Inc. (Morningstar Research)
Nov-21-25 06:50PM	Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know (StockStory)
Nov-19-25 04:30PM	Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
Nov-18-25 09:50AM	Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-11-25 11:36PM	2 Healthcare Stocks to Keep an Eye On and 1 We Find Risky (StockStory)
07:55AM	Penumbra Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand (Zacks)
Nov-10-25 02:26PM	Do Options Traders Know Something About Penumbra Stock We Don't? (Zacks)
09:45AM	Why Penumbra (PEN) is a Top Growth Stock for the Long-Term (Zacks)
Nov-07-25 08:45AM	Penumbra price target raised to $355 from $350 at Canaccord (TipRanks)
Nov-06-25 04:02PM	Penumbra Shoots For A Breakout On 'Another Impressive Quarter' (Investor's Business Daily) +17.32%
11:36AM	Why Penumbra (PEN) Stock Is Up Today (StockStory)
09:01AM	Analyst Report: Penumbra, Inc. (Morningstar Research)
12:03AM	Penumbra Inc (PEN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and New Product ... (GuruFocus.com)
Nov-05-25 06:30PM	Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:00PM	Penumbra (PEN) Q3 Earnings and Revenues Beat Estimates (Zacks)
05:12PM	Penumbra (NYSE:PEN) Delivers Strong Q3 Numbers, Stock Jumps 18.7% (StockStory)
04:56PM	Penumbra: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 10:12PM	What To Expect From Penumbra's (PEN) Q3 Earnings (StockStory)

Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.

Co-FounderMr. Adam Elsesser J.D.

PresidentMs. Shruthi Narayan

Co-Founder & DirectorDr. Arani Bose M.D.

Chief Financial OfficerMs. Maggie S. Yuen

Chief Accounting OfficerMr. Lambert Shiu

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Grewal Harpreet	Director	Apr 02 '26	Sale	328.22	100	32,822	8,719	Apr 06 08:02 PM
Grewal Harpreet	Director	Apr 02 '26	Proposed Sale	328.22	100	32,822		Apr 02 03:59 PM
Yuen Maggie	Chief Financial Officer	Mar 02 '26	Sale	342.30	2,432	832,474	18,353	Mar 04 07:31 PM
MAGGIE YUEN	Officer	Mar 02 '26	Proposed Sale	342.30	2,432	832,474		Mar 02 04:11 PM
Grewal Harpreet	Director	Jan 06 '26	Sale	312.64	186	58,151	8,230	Jan 08 09:06 PM
Wilder Thomas	Director	Jan 02 '26	Sale	310.72	186	57,794	0	Jan 06 07:33 PM
Grewal Harpreet	Director	Jan 06 '26	Proposed Sale	312.64	186	58,151		Jan 06 03:52 PM
THOMAS WILDER	Director	Jan 02 '26	Proposed Sale	310.72	186	57,794		Jan 02 04:02 PM
Bose Arani	Director	Dec 11 '25	Sale	308.82	15,000	4,632,292	258,462	Dec 15 07:30 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Dec 05 '25	Sale	300.13	300	90,039	63,836	Dec 09 08:01 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Dec 01 '25	Sale	294.94	600	176,966	64,136	Dec 03 07:45 PM
Grewal Harpreet	Director	Dec 02 '25	Sale	292.98	100	29,298	8,416	Dec 03 07:44 PM
Grewal Harpreet	Director	Dec 02 '25	Proposed Sale	292.98	100	29,298		Dec 02 03:59 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Nov 25 '25	Sale	300.06	1,800	540,108	64,736	Nov 26 07:36 PM
Bose Arani	Director	Nov 25 '25	Sale	300.19	7,500	2,251,425	275,261	Nov 26 07:36 PM
Bose Arani	Director	Nov 21 '25	Sale	290.56	7,500	2,179,212	282,761	Nov 25 07:59 PM
Johanna Roberts	Officer	Nov 25 '25	Proposed Sale	298.11	2,100	626,031		Nov 25 05:20 PM
Arani Bose	Affiliate	Nov 21 '25	Proposed Sale	279.79	30,000	8,393,700		Nov 21 05:21 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Nov 10 '25	Sale	266.98	600	160,189	63,657	Nov 12 07:32 PM
Grewal Harpreet	Director	Nov 04 '25	Sale	227.58	186	42,330	8,516	Nov 06 07:31 PM
Grewal Harpreet	Director	Nov 04 '25	Proposed Sale	227.58	186	42,330		Nov 04 03:53 PM
Grewal Harpreet	Director	Oct 02 '25	Sale	248.61	186	46,241	8,702	Oct 03 07:32 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Oct 01 '25	Sale	249.70	600	149,820	64,257	Oct 03 07:31 PM
Wilder Thomas	Director	Oct 01 '25	Sale	253.93	186	47,231	186	Oct 03 07:30 PM
Grewal Harpreet	Director	Oct 02 '25	Proposed Sale	248.61	186	46,241		Oct 02 04:03 PM
Johanna Roberts	Officer	Oct 01 '25	Proposed Sale	253.22	1,800	455,796		Oct 01 04:08 PM
THOMAS WILDER	Director	Oct 01 '25	Proposed Sale	253.93	186	47,231		Oct 01 04:01 PM
Grewal Harpreet	Director	Sep 02 '25	Sale	272.19	186	50,627	8,888	Sep 04 07:36 PM
Elsesser Adam	CEO	Sep 03 '25	Option Exercise	30.00	27,980	839,400	198,260	Sep 04 07:36 PM
Elsesser Adam	CEO	Sep 03 '25	Sale	269.65	15,800	4,260,457	182,460	Sep 04 07:36 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Sep 02 '25	Sale	270.58	600	162,347	64,857	Sep 04 07:36 PM
ADAM ELSESSER	Officer	Sep 03 '25	Proposed Sale	269.65	15,800	4,260,404		Sep 03 04:51 PM
Grewal Harpreet	Director	Sep 02 '25	Proposed Sale	272.19	186	50,627		Sep 02 03:59 PM
Elsesser Adam	CEO and President	Aug 20 '25	Option Exercise	30.00	27,976	839,280	186,180	Aug 22 07:48 PM
Elsesser Adam	CEO and President	Aug 20 '25	Sale	254.53	15,900	4,046,952	170,280	Aug 22 07:48 PM
ADAM ELSESSER	Officer	Aug 20 '25	Proposed Sale	254.53	15,900	4,046,989		Aug 20 04:28 PM
Yuen Maggie	Chief Financial Officer	Aug 15 '25	Option Exercise	158.30	724	114,609	13,667	Aug 15 07:49 PM
Yuen Maggie	Chief Financial Officer	Aug 13 '25	Sale	250.00	2,000	500,000	12,943	Aug 15 07:49 PM
Bose Arani	Director	Aug 13 '25	Sale	250.65	12,000	3,007,776	558	Aug 15 07:44 PM
Wilder Thomas	Director	Aug 12 '25	Sale	240.16	372	89,340	372	Aug 13 07:44 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Aug 11 '25	Sale	238.94	600	143,363	65,457	Aug 13 07:40 PM
Arani Bose	Affiliate	Aug 13 '25	Proposed Sale	248.55	12,000	2,982,600		Aug 13 05:24 PM
MAGGIE YUEN	Officer	Aug 13 '25	Proposed Sale	250.00	2,000	500,000		Aug 13 04:04 PM
THOMAS WILDER III	Director	Aug 12 '25	Proposed Sale	240.16	372	89,340		Aug 12 04:05 PM
Elsesser Adam	CEO and President	Aug 06 '25	Option Exercise	30.00	27,976	839,280	174,234	Aug 08 08:06 PM
Elsesser Adam	CEO and President	Aug 06 '25	Sale	238.20	16,030	3,818,363	158,204	Aug 08 08:06 PM
ADAM ELSESSER	Officer	Aug 06 '25	Proposed Sale	238.20	16,030	3,818,397		Aug 06 04:48 PM
Elsesser Adam	CEO and President	Jul 23 '25	Option Exercise	30.00	27,976	839,280	162,408	Jul 25 07:32 PM
Elsesser Adam	CEO and President	Jul 23 '25	Sale	233.16	16,150	3,765,574	146,258	Jul 25 07:32 PM
ADAM ELSESSER	Officer	Jul 23 '25	Proposed Sale	233.16	16,150	3,765,610		Jul 23 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PEN

Penumbra Inc

Upgrade your Finviz experience